Table 1 Clinical characteristics of all patients with BSI-Kpn
From: Genomic and immunocyte characterisation of bloodstream infection caused by Klebsiella pneumoniae
Parameter/category | CSKP (N = 92) | CRKP (N = 81) | P-value |
|---|---|---|---|
Gender, male, N (%) | 59 (64.1) | 54 (66.7) | 0.727 |
Age (years) | 52.1 ± 15.7 | 52.7 ± 14.5 | 0.81 |
APACHE-II score | 10.8 ± 5.7 | 12.7 ± 5.7 | 0.026 |
SOFA score | 5.2 ± 4 | 7.4 ± 4.1 | 0.001 |
Prior chemotherapy or radiotherapy, N (%) | 17 (18.5) | 16 (19.8) | 0.831 |
Prior corticosteroid therapy, N (%) | 28 (30.4) | 38 (46.9) | 0.026 |
Prior immunosuppressant use, N (%) | 19 (20.7) | 30 (37) | 0.017 |
Comorbid illness, N (%) | |||
Diabetes | 23 (25.0) | 10 (12.3) | 0.035 |
Hepatitis | 24 (26.1) | 30 (37.0) | 0.121 |
Tumor | 23 (25.0) | 22 (27.2) | 0.747 |
Hypertension | 34 (37.0) | 26 (32.1) | 0.503 |
Coronary heart disease | 1 (1.1) | 4 (4.9) | 0.131 |
Cerebral infarction | 4 (4.3) | 4 (4.9) | 0.854 |
Renal insufficiency | 21 (22.8) | 17 (21.0) | 0.771 |
Trauma | 4 (4.3) | 7 (8.6) | 0.248 |
Organ transplant | 20 (21.7) | 30 (37.0) | 0.027 |
Invasive procedures, N (%) | |||
Mechanical ventilation | 34 (37.0) | 56 (69.1) |  < 0.000 |
Hemodialysis | 17 (18.5) | 27 (33.3) | 0.025 |
Urinary catheterization | 46 (50) | 62 (76.5) |  < 0.000 |
Arterial catheterization | 44 (47.8) | 70 (86.4) |  < 0.000 |
Stomach tube | 34 (37.0) | 55 (67.9) |  < 0.000 |
Bronchofibroscope use | 11 (12.0) | 13 (16.0) | 0.437 |
Wound drainage tube use | 65 (70.7) | 71 (87.7) | 0.004 |
Laboratory examination | |||
White blood cell (10E9/L) | 9.8 ± 7.1 | 8.3 ± 6.3 | 0.139 |
Neutrophil percentage (%) | 82.7 ± 21.7 | 83.5 ± 21.4 | 0.805 |
Hemoglobin (g/L) | 96.5 (78.3–125.5) | 77.0 (65.0–90.5) |  < 0.000 |
Platelet (10E9/L) | 128.1 ± 111.2 | 100.0 ± 91 | 0.073 |
Hypersensitivity C reactive protein (mg/L) | 95.1 ± 79.6 | 85.5 ± 66.5 | 0.39 |
Procalcitonin (ng/ml) | 3.4 (0.8–16.1) | 2.6 (0.8–9.5) | 0.039 |
Albumin (g/L) | 33.2 ± 5.8 | 34.8 ± 5.6 | 0.061 |
Alanine transaminase (U/L) | 37.0 (16.3–96.5) | 48.0 (17.0–169.5) | 0.151 |
Aspartate aminotransferase (U/L) | 40.0 (20.0–76.8) | 45.0 (18.5–122.0) | 0.482 |
Cholinesterase (U/L) | 3941.8 ± 1894.2 | 3422.9 ± 1610.9 | 0.056 |
Total bilirubin (μmol/L) | 99.1 ± 463.7 | 74.0 ± 99.8 | 0.633 |
Serum creatinine (μmol/L) | 152.6 ± 213.9 | 152.0 ± 204.4 | 0.985 |
International normalised ratio (INR) | 1.3 ± 0.4 | 1.3 ± 0.3 | 0.762 |
Antimicrobial therapy after diagnosis, N (%) | |||
Carbapenems | 68 (73.9) | 49 (60.5) | 0.06 |
β-lactam and/or β-lactamase inhibitor | 54 (58.7) | 52 (64.2) | 0.459 |
Cephalosporins | 11 (12) | 6 (7.4) | 0.316 |
Fluoroquinolone | 19 (20.7) | 16 (19.8) | 0.883 |
Aminoglycoside | 9 (9.8) | 25 (30.9) |  < 0.000 |
Fosfomycin | 7 (7.6) | 17 (21.0) | 0.011 |
Tigecycline | 11 (12.0) | 46 (56.8) |  < 0.000 |
Polymyxin B | 9 (9.8) | 26 (32.1) |  < 0.000 |
Ceftazidime-avibactam | 5 (5.4) | 32 (39.5) |  < 0.000 |
Combination therapy | 60 (65.2) | 67 (82.7) | 0.009 |
30-day mortality, N (%) | 12 (13.0) | 30 (37.0) |  < 0.000 |